Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
INGAP Peptide acetate is the active ingredient of INGAP Peptide Solution for Injection. It is
being developed as an antidiabetic agent for the restoration of endogenous insulin secretion
in patients with type 1 diabetes mellitus (T1DM) and in insulin-deficient patients with type
2 diabetes mellitus (T2DM). This clinical study is designed to generate additional data
regarding the appropriate dose and dosing regimen and to evaluate safety and efficacy in
patients with T1DM.